StimLabs Launches Allacor P for Advanced Wound Care

StimLabs has launched Allacor P, a dehydrated human umbilical cord particulate device for acute and chronic wound management. The device, cleared by the FDA in February 2024 alongside Corplex P, is designed to conform to complex and irregular wound surfaces.

Allacor P is the first graft derived from human umbilical cord extracellular matrix (ECM), retaining key components such as collagen I and hyaluronic acid, which support healing and adaptability across clinical scenarios. The product’s particulate format allows for precise application in diverse wound types.

Following FDA clearance, StimLabs has focused on collecting clinical feedback and building scientific evidence to guide its use in real-world healthcare settings. The device has also received an A Code, enabling broader adoption across care sites.

StimLabs, with a focus on regenerative medicine and wound care, continues to advance clinical research, including multi-centre trials of its fenestrated placental membrane allograft, Relese, for hard-to-heal wounds.

06-01-2026